AI & Data Analytics

Open-source, collaborative, and blockchain constrained, Morpheo is starting with sleep disorders and looking far beyond.

“Sometimes we realize, 'Watson got that one right and we got it wrong," one of its trainers at MSKCC said. Still, it has work to do.

"It improves how kidneys are allocated, and it improves the rationalizations of doctors and patients."

One of the co-authors of NEJM article on inflated machine learning expectations spoke to HCA News about what inspired his commentary.

Antov, Deeken, and Killian return with five more tips on how health companies can catch up to other industries in their use of analytics for business.

Data analytics and accountability are key, according to researchers at Oregon Health and Sciences University.

Apparently “come to us, we have no infections,” doesn’t qualify as adequate reporting.

In part 2 of this week's C-Suite Q&A, we continue our conversation with David Delaney, MD.

"At SAP, we're across 25 different sectors, and 23 or 24 of them are quite a ways beyond healthcare."

An original Healthcare Research & Analytics survey found that many in healthcare know the name, but not the potential.

The SoftBank Vision Fund bestowed more than ten figures on the rising biotech company, which also announced yet another subsidiary.

Predictive modeling may add a layer of protection against the common virus.

SAP Health's CMO on ways to make the most out of analytics.

“Visionary organizations already know the train has left the station,” Yele Aluko, MD, says.

A new study shows that tracking Google searches may be an effective means of monitoring mosquito-borne disease activity.

Your weekly roundup of the 5 most popular stories on iDigitalhealth.com. This week’s highlights include a Q&A with a healthcare payment system thought leader, a report on IT treats against smaller health facilities, and a country-by-country look at cybersecurity.

A recent study linked cancer cell shapes to gene expression.

The study showed that Watson could produce actionable clinical data in 10 minutes that would ordinarily take humans 160 hours.

In Part 2 of the interview, Bradley speaks to what makes analytics in healthcare unique, the breadth and integrity of provider data, and how better financial interactions with patients may improve their perception of healthcare providers

The University of Aberdeen has received nearly $10 million to use AI to determine the human behaviors that lead to attacks, and how to modify them.

“All of the goodwill that’s been accumulated when we have the patient in our care, that’s thrown out the window because we haven’t maintained the patient experience in the financial relationship we have with the patient.”

"Two years ago people were still saying 'well, let’s see what happens to these programs.' Now, everyone is saying that it isn’t a question of 'if', it’s 'at what pace?'"

"Sometimes serendipity smiles." Dr. Drouin, in the first part of our interview, spoke to the needs his company aims to fill, the pursuit of value-based care, and the process of leaving a career and getting a startup off the ground.

“Big data is not just about big numbers, but also the patterns that can explain important health trends,” says the NIH's Grace Peng. A new Stanford study used some huge data to track obesity.

Many healthcare product companies continue to downplay the potential impact that investments in data analytics could have on their business.

"Whether such artificial-intelligence systems are ‘smarter’ than human practitioners makes for a stimulating debate—but is largely irrelevant," they write.

Can drug manufacturers use colossal swaths of data to deliver new pharmaceuticals more efficiently and cost-effectively? And if so, will those savings some day make their way to the patients?

"We are pitting the enthusiasm of the futurists...against the public health perspective that says ‘be careful what you screen for,’” the prominent genomicist says.

The FDA, GINA, and variants of unknown significance all muddy the waters of genomic research and data storage.

Certainly, Walton believes greatly in the potential of genomics to change medicine at its core, but the obstacles preceding that shift are numerous and substantial, he argued.